Navigation Links
New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting
Date:6/3/2010

HACKENSACK, N.J., June 3 /PRNewswire/ -- The John Theurer Cancer Center at Hackensack University Medical Center announced today important research findings that will be presented at the American Society of Clinical Oncology (ASCO) annual meeting taking place June 4 – 8, 2010 in Chicago. Research highlights include a comparison of first-line treatments for an aggressive form of lymphoma, the efficacy and safety of a new genetically engineered cancer therapy, and the value of a commonly used tool for staging lymphoma. These findings are only three of 16 studies that will be discussed by researchers from the John Theurer Cancer Center.  

"We are excited to present significant research findings, particularly in the area of hematological malignancies, as part of our continued commitment to advance cancer research," said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., Chairman and Executive Administrative Director, John Theurer Cancer Center. "The studies we will present at ASCO represent just a small sample of the work that we do to improve outcomes not just for our patients, but for the cancer community as a whole."

Research to be presented at ASCO by researchers at the John Theurer Cancer Center will showcase treatment advancements for cancers of the blood, including lymphoma and multiple myeloma. Poster presentation highlights in these areas include:  

Rituximab, fludarabine, mitoxantrone, and dexamethasone (R-FND) combination may help patients with relapsed indolent B-cell lymphoma. (Abstract number 8078; poster session, June 5, 8:00 a.m.12:00 p.m.)

'/>"/>

SOURCE John Theurer Cancer Center
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Studies Demonstrate Early Stage Detection and Economic Benefits of a Blood-Based Test for Lung Cancer
2. Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
3. Health Robotics South East Asia Wins two key Cancer Therapy Outsourcing Projects in Malaysia and Thailand
4. NewLink Initiates Pivotal Phase 3 Clinical Trial of HyperAcute(R)-Pancreas Immunotherapy for Resected Pancreatic Cancer
5. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Pancreatic Cancer Clinical Trial
6. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
7. Oncolytics Biotech(R) Inc. Announces Opening of Enrollment in Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
8. Tumor-Targeted Rexin-G Prolongs Survival in Gemcitabine-Resistant Metastatic Pancreas Cancer in Advanced Phase I and II Studies (ASCO 2010)
9. Tumor-Targeted Nanoparticle-based Gene Delivery Provides Evidence of Therapeutic Vaccination in Patients with Metastatic Cancer (ASCO 2010)
10. Abviva Details Patent Information for its Breast Cancer Risk Assessment Technology
11. Oncolytics Biotech(R) Inc. Announces Phase I Colorectal Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... Mich., March 26, 2015 Neogen Corporation (NASDAQ: ... for the third quarter of fiscal 2015, which ended ... the prior year,s $6,575,000. Earnings per share in the ... ago. Current year-to-date net income increased 17% over prior ... $20,621,000, or $0.56 per share, for the same period ...
(Date:3/26/2015)... (PRWEB) March 26, 2015 "In America," the ... the United States that is hosted by legendary film actor ... topic of botany in an upcoming segment. , Botany ... in reality it is actually quite a bit more complicated ... of different types of living organisms, from the smallest bacteria ...
(Date:3/25/2015)... of the most attractive in the emerging European region, ... economy and increasing government investment in healthcare, according to ... is set to grow at twice the pace of ... annually reaching an approximate market value of $43-60 billion ... Green Cross provides total healthcare solutions that address the ...
(Date:3/25/2015)... , March 25, 2015 Optimal Research, ... Vaccine Industry Excellence (ViE) Award "Best Clinical Site or ... year that Optimal has been selected as a nominee ... Congress, receiving a "Highly Recommended" distinction in 2014. The ... of the efforts, accomplishments, and positive contributions of companies ...
Breaking Biology Technology:Neogen reports 13% increase in net income 2Neogen reports 13% increase in net income 3Neogen reports 13% increase in net income 4Neogen reports 13% increase in net income 5Neogen reports 13% increase in net income 6Neogen reports 13% increase in net income 7Neogen reports 13% increase in net income 8Optimal Research Nominated 2015 Vaccine Industry Excellence (ViE) Award 2
... FRANCISCO, Calif., May 15 Poniard Pharmaceuticals, Inc. (Nasdaq: ... oncology, today announced that it has filed a shelf ... Exchange Commission (SEC) that, when declared effective by the ... offer and sell up to $60 million aggregate amount ...
... DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or ... financial results for the first quarter of 2009. DOR,s ... $0.5 million compared to $0.7 million for the first ... attributable to decreased research and development amounts drawn down ...
... -- Tiens Biotech Group (USA), Inc. (the,"Company" or "Tiens", NYSE ... financial results for the first quarter ended March 31, 2009. ... of 2009 increased 42% to $18.2 million,compared to $12.8 million ... international sales. , Net income attributable ...
Cached Biology Technology:Poniard Pharmaceuticals Files Shelf Registration 2Poniard Pharmaceuticals Files Shelf Registration 3DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments 2DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments 3DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments 4DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments 5Tiens Biotech Group (USA) Reports First Quarter Results 2Tiens Biotech Group (USA) Reports First Quarter Results 3Tiens Biotech Group (USA) Reports First Quarter Results 4Tiens Biotech Group (USA) Reports First Quarter Results 5Tiens Biotech Group (USA) Reports First Quarter Results 6Tiens Biotech Group (USA) Reports First Quarter Results 7Tiens Biotech Group (USA) Reports First Quarter Results 8Tiens Biotech Group (USA) Reports First Quarter Results 9Tiens Biotech Group (USA) Reports First Quarter Results 10Tiens Biotech Group (USA) Reports First Quarter Results 11
(Date:3/11/2015)... 11, 2015   The Sync Project™ ... scientifically measure and harness music to improve health. ... and objective measurements of physiology, enabling the study ... in large populations. It is designed for medical ... perform rigorous studies and accelerate the discovery of ...
(Date:3/10/2015)... 10, 2015 Transforming How We ... "Personalized Medicine in Human Space Flight" by ... Goodwin , Ph.D. was recently featured by Springer Science ... years. Specifically, "Personalized Medicine in Human Space ... published in 2013 and 2014 from Springer in the ...
(Date:3/10/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce ... been named the "Number One Best Tech Gift ... Modern ( http://www.rethinkmodern.com/ ) is a web magazine focused ... that have a unique function or design.  ...
Breaking Biology News(10 mins):Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4
... UN report provides definitive answers and ways to repair lives ... eventually die of radiation exposure from the Chernobyl nuclear power ... of more than 100 scientists has concluded. , As of ... to radiation from the disaster, almost all being highly exposed ...
... September the chlorophyll starts to disappear from the leaves of plants. ... the explosion of colors we now have in store. A research ... protein that helps bring out the color splendor of plants in ... in the scientific journal PNAS, Proceedings of the National Academy ...
... Using sunlight to power our homes and offices is an ... better use of solar energy. The study of photosynthesis in ... almost 100% of the sun-light reaching them, and how they ... Haumann and Holger Dau, from the Freie Universit├Ąt Berlin, used ...
Cached Biology News:Chernobyl: The true scale of the accident 2Chernobyl: The true scale of the accident 3Chernobyl: The true scale of the accident 4Chernobyl: The true scale of the accident 5Chernobyl: The true scale of the accident 6Chernobyl: The true scale of the accident 7Chernobyl: The true scale of the accident 8Chernobyl: The true scale of the accident 9Chernobyl: The true scale of the accident 10Chernobyl: The true scale of the accident 11Chernobyl: The true scale of the accident 12Chernobyl: The true scale of the accident 13Chernobyl: The true scale of the accident 14Chernobyl: The true scale of the accident 15Chernobyl: The true scale of the accident 16Protein behind autumn color splendor identified 2Plants reveal a secret and bring researchers nearer a cleaner future 2
albumin from bovine serum (BSA), Alexa Fluor® 647 conjugate...
Superior homology search software - in all the flavours of blast, with increased sensitivity and speed. Free windows version for academic use....
... (6-28) (human, bovine, porcine, rat) ... (VIP) receptor antagonist. This carboxy-terminal ... be twofold more potent than ... antagonists. Storage: ...
Superior homology search software - in all the flavours of blast, with increased sensitivity and speed...
Biology Products: